PureTech Health (LON:PRTC)‘s stock had its “buy” rating reissued by Peel Hunt in a report released on Tuesday, April 2nd, ThisIsMoney.Co.Uk reports.
PRTC has been the subject of a number of other research reports. Liberum Capital reaffirmed a “buy” rating on shares of PureTech Health in a report on Thursday, March 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 255 ($3.33) target price on shares of PureTech Health in a report on Thursday, March 7th.
Shares of PRTC traded up GBX 1.50 ($0.02) during trading hours on Tuesday, hitting GBX 188 ($2.46). The stock had a trading volume of 129,307 shares, compared to its average volume of 71,917. The company has a debt-to-equity ratio of 5.73, a current ratio of 0.97 and a quick ratio of 0.94. PureTech Health has a fifty-two week low of GBX 135 ($1.76) and a fifty-two week high of GBX 189.50 ($2.48). The stock has a market cap of $526.85 million and a P/E ratio of 7.29.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.